ArticleCureus2025
Cardiac Amyloidosis Mimicking Heart Failure With Preserved Ejection Fraction: Evaluating Self-Reported Red Flags in Routine Clinical Practice.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Cardiac amyloidosis is often underdiagnosed and can mimic heart failure with preserved ejection fraction (HFpEF), particularly in older adults. Most cases of cardiac amyloidosis are discovered in the late stages as a result of overlapping clinical symptoms. This study addresses whether patients with symptomatic heart failure and associated red flag features of cardiac amyloidosis have a worse functional status and quality of life than patients with classical HFpEF. Methodology This cross-sectional study was conducted between July 2024 and May 2025, in Lahore, Pakistan, in the cardiology departments of hospitals and clinics. Participants were recruited using a convenience method, in which 389 adults experiencing heart failure symptoms were interviewed. Data were collected using a structured, self-reported questionnaire that included demographic items, a seven-item checklist of red flag symptoms (e.g., carpal tunnel syndrome, unintentional weight loss, dizziness, and unexplained shortness of breath), and validated tools of physical limitations and quality of life. To assess the association between red flag symptoms and clinical outcomes, non-parametric statistical tests, correlation tests, and ordinal logistic regression were employed using SPSS Version 26 (IBM Corp., Armonk, NY, USA). Results Among 389 participants (mean age 51.4 ± 8.8 years), those with two or more red flags (suspected cardiac amyloidosis group) had significantly worse NYHA functional class scores (U = 954.500, p < 0.001) and lower quality of life scores (U = 580.000, p < 0.001) compared to typical HFpEF patients. The suspected cardiac amyloidosis group had a median New York Heart Association (NYHA) score of 3.00 (interquartile range (IQR) = 3.00-4.00) and a median quality of life score of 42.00 (IQR = 32.00-54.00). The red flag burden was positively correlated with worse functional status (r = 0.26, p < 0.01) and negatively correlated with quality of life (r = -0.32, p < 0.01). Logistic regression showed that poorer functional status and quality of life were significant predictors of suspected cardiac amyloidosis classification. Conclusions The results showed that an increase in the burden of red flag symptoms is linked to greater physical limitation and poorer quality of life among heart failure patients. Although no diagnostic imaging was conducted in this study, the symptom-based screening tool can complement echocardiographic vigilance in clinical practice, helping identify individuals at risk for cardiac amyloidosis who may benefit from further investigations. Further studies are necessary to validate these tools and analyze the ways of implementing them within the early referral process.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.